Aminophylline toxicity.
Aminophylline therapy has undergone change in the past decade. With the changes in usage and dosage forms, the frequency of toxicity in the pediatric population, especially in adolescents, has increased dramatically. Two distinct patterns, chronic and acute, have been recognized and treatment methods for both are changing. Table 4 summarizes the emerging state-of-the-art therapy for aminophylline toxicity. Judging from the activity seen in the literature, investigation into aminophylline toxicity will continue to be a priority. We will see a greater understanding of the disease process and a refining of the therapeutic process. The ultimate goal is the elimination of mortality and the minimization of morbidity from aminophylline toxicity.
D000293:Adolescent; D000628:Aminophylline / Q000009:adverse effects* / Q000378:metabolism / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000139:chemically induced; D002648:Child; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D007700:Kinetics; D009422:Nervous System Diseases / Q000139:chemically induced; D013806:Theophylline / Q000009:adverse effects / Q000627:therapeutic use
D000628:Aminophylline; D013806:Theophylline